Li Simon 4
4 · SCICLONE PHARMACEUTICALS INC · Filed Oct 16, 2017
Insider Transaction Report
Form 4
Li Simon
Director
Transactions
- Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2017-10-13$6.08/sh−30,000$182,400→ 0 totalExercise: $5.10Exp: 2024-06-12→ Common Stock (30,000 underlying) - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2017-10-13$0.28/sh−30,000$8,400→ 0 totalExercise: $10.90Exp: 2027-06-08→ Common Stock (30,000 underlying) - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2017-10-13$6.33/sh−50,000$316,500→ 0 totalExercise: $4.85Exp: 2023-01-10→ Common Stock (50,000 underlying) - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2017-10-13$6.05/sh−12,500$75,625→ 0 totalExercise: $5.13Exp: 2023-06-27→ Common Stock (12,500 underlying) - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2017-10-13$2.03/sh−30,000$60,900→ 0 totalExercise: $9.15Exp: 2025-06-11→ Common Stock (30,000 underlying)
Footnotes (6)
- [F1]Under its terms the option became exercisable in installments at the rate of one-third of the shares subject to the option at the end of each anniversary of the date of grant (January 10, 2013), and became immediately exercisable and vested in full as of January 10, 2016.
- [F2]The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
- [F3]Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 27, 2013), and became immediately exercisable and vested in full as of June 27, 2014.
- [F4]Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 12, 2014), and became immediately exercisable and vested in full as of June 12, 2015.
- [F5]Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016.
- [F6]Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 8, 2017), and became immediately exercisable and vested in full as of the date ten (10) days prior to the Merger.